慢性HIV-1感染分析性治疗中断后病毒反弹的时间与幅度:APACHE研究
该前瞻性单臂概念验证研究纳入9例慢性HIV-1感染者,接受ART且病毒载量抑制超过10年、HIV-DNA低,进行严格监测下的分析性治疗中断。所有受试者均出现确认的病毒反弹,中位时间21天,反弹幅度与ART前HIV-RNA、CD4最低值等相关。尽管长期抑制和低储存库,病毒反弹仍早期且一致出现。
要点
- 长期病毒抑制且低HIV-DNA者中断ART后仍全部快速反弹。
- 反弹中位时间21天,需严密监测。
- 反弹幅度与ART前病毒载量、CD4水平等相关。
核心结论
- 即使HIV病毒载量抑制超过10年且储存库低,所有受试者在分析性治疗中断后均出现早期且一致的病毒反弹。
研究设计与样本
- 前瞻性、开放标签、单臂、非随机概念验证研究(NCT03198325),纳入9例慢性HIV-1感染者,接受ART且HIV-RNA<50 copies/mL≥10年、无残余病毒血症≥5年、CD4+>500 cells/mm3、HIV-DNA<100 copies/106 PBMCs。
主要发现
- 所有9例受试者均发生确认的病毒反弹,反弹时HIV-RNA中位数为4.84 log10 copies/mL(IQR 3.47-6.47)。
- 病毒反弹中位时间为21天(范围14-56天)。
- 恢复ART后,所有受试者在中位88天(范围15-197天)内达到HIV-RNA<50 copies/mL。
- 无严重不良事件发生;1例受试者出现急性逆转录病毒综合征。
- 病毒反弹幅度与ART前HIV-1 RNA(Spearman r=0.786,P=0.036)、CD4最低值(r=-0.800,P=0.010)、基线CD4+(r=-0.667,P=0.049)及病毒载量检测不到的年数(r=-0.717,P=0.030)显著相关;基线因素与反弹时间无显著相关性。
临床怎么用
- 对于长期病毒抑制且低储存库的慢性HIV感染者,分析性治疗中断仍会导致快速病毒反弹,需在严密监测下进行并准备及时恢复ART。
局限性
- 样本量小(9例),为非随机单臂研究,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite the fact that there are individuals who have chronic HIV infection, few studies have investigated ART interruption in this setting. The aim of this study was to evaluate the ability to spontaneously control viral replication during analytical treatment interruption (ATI) in adults with chronic HIV-1 infection, on ART, with suppressed viraemia for >10 years and with a low reservoir. PATIENTS AND METHODS: This was a prospective, open-label, single-arm, non-randomized, proof-of-concept study (NCT03198325) of subjects with chronic HIV-1 infection, HIV-RNA <50 copies/mL for ≥10 years, without residual viraemia for ≥5 years, CD4+ >500 cells/mm3, HIV-DNA <100 copies/106 PBMCs and without comorbidities or AIDS-defining diseases. Enrolled patients were strictly monitored. The ART regimen in use at ATI was resumed in the case of confirmed viral rebound (CVR, two consecutive HIV-RNA >50 copies/mL). Results are reported as median (IQR). RESULTS: Nine patients underwent ATI. All participants experienced CVR [4.84 (IQR: 3.47-6.47) HIV-RNA log10 copies/mL] after ATI at a median time of 21 days (range 14-56) and restarted ART. After ART resumption, all the subjects achieved HIV-RNA <50 copies/mL in a median of 88 days (range 15-197). No serious adverse event occurred; one subject experienced acute retroviral syndrome. No significant correlation between baseline factors and time to viral rebound was observed, while the magnitude of viral rebound was significantly associated with pre-ART HIV-1 RNA (Spearman r = 0.786, P = 0.036), nadir CD4+ (Spearman r = -0.800, P = 0.010), baseline CD4+ (Spearman r = -0.667, P = 0.049) and years with undetectable viral load (Spearman r = -0.717, P = 0.030). CONCLUSIONS: Despite a long period of HIV viral load suppression and a low viral reservoir, early and consistent viral rebound was observed during ATI in all subjects.
引用
- Castagna A, Muccini C, Galli L, et al. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). J Antimicrob Chemother. 2019. PMID: 31225610. doi:10.1093/jac/dkz138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。